Samsung Biologics Co.,Ltd. (KRX:207940)

Market Cap	78.46T
Revenue (ttm)	5.50T
Net Income (ttm)	1.60T
Shares Out	46.29M
EPS (ttm)	34,474.63
PE Ratio	49.17
Forward PE	42.21
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,856
Average Volume	43,227
Open	1,700,000
Previous Close	1,706,000
Day's Range	1,692,000 - 1,703,000
52-Week Range	1,420,683 - 1,944,983
Beta	0.20
RSI	48.98
Earnings Date	Jan 20, 2026

About Samsung Biologics

Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates through Contract Development and Manufacturing Organization (CDMO), and Biopharmaceutical Development and Commercialization segments. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, fini...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 4,770
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 207940

Financial Performance

In 2024, Samsung Biologics's revenue was 4.55 trillion, an increase of 23.08% compared to the previous year's 3.69 trillion. Earnings were 1.08 trillion, an increase of 26.31%.